■ MATERIAL WEAKNESS WATCH
Nasdaq · CIK 0002004489

BMGL Basel Medical Group Ltd

F
30 / 100
Material weaknesses
2
Restatements
1
Auditor changes
1
Late filings
0
Quarters with open weakness
1
Remediations
0
Deductions
70
Remediation credit
0

Trailing 24 months from 2024-11-07. Rubric v1. How this is scored.

Disclosures, in the company's words

  • Auditor change20-F · filed 2026-10-30 · Item 16Fsource filing ↗
    “The Company appointed NLA DFK Assurance PAC ( NLA DFK ) as its independent registered public accounting firm, effective on June 30, 2025.”
  • Material weakness20-F · filed 2026-10-30 · Item 15source filing ↗
    “This identified material weakness is associated with a lack of adequately skilled staff possessing IFRS knowledge for financial reporting purposes, thereby affecting the proper adherence to IFRS and SEC requirements.”
  • Controls not effective20-F · filed 2026-10-30 · Item 15source filing ↗
    “Based on that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures as of June 30, 2026 were not effective as described below.”
  • Material weakness20-F · filed 2026-10-30source filing ↗
    “In order to address and resolve the foregoing material weakness, we will implement measures designed to improve our internal control over financial reporting to remediate this material weakness, including hiring outside financial personnel with requisite training and experience in the preparation of financial statements”
  • Restatement / non-reliance20-F · filed 2026-10-30source filing ↗
    “In March 2026, we filed an amended annual report on Form 20-F/A, which included a new unqualified audit opinion and amended and restated our audited consolidated financial statements for the fiscal years ended June 30, 2025 and 2024 and the related notes thereto.”

Filings read

Think something here is wrong? Request a correction. Open corrections hide the affected disclosure until resolved.